Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Rina-S, Ic
Endometrial Cancer, Recurrent Or Progressive Endometrial Cancer
Phase III
Not Yet Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Sep 09, 2025
―
Bevacizumab, Bnt327, Bnt314, Soc Chemotherapy Treatment 1, Soc Chemotherapy Treatment 2
Metastatic Colorectal Cancer
Phase I/II
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Jul 09, 2025
―
Pembrolizumab, Acasunlimab
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage Iiib, Iiic, Or Iiid), Metastatic Cutaneous Melanoma (Stage Iv)
Phase II
Recruiting
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
May 14, 2025
―
Tivdak
Cervical Cancer
Phase IV
Recruiting
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Apr 15, 2025
―
Gen1078
Malignant Solid Tumor
Phase I/II
Terminated
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
Jan 08, 2025
―
Gen1286
Advanced Solid Tumor
Phase I/II
Recruiting
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Nov 11, 2024
―
Pembrolizumab, Docetaxel, Acasunlimab
Pd-L1-Positive Metastatic Nsclc
Phase III
Recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Oct 08, 2024
―
Gemcitabine, Pegylated Liposomal Doxorubicin (Pld), Paclitaxel, Topotecan, Rina-S
Platinum-Resistant Ovarian Cancer
Phase III
Recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Sep 20, 2024
―
Gen1057, Premedication
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor
Phase I
Recruiting
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
Aug 26, 2024
―
Pembrolizumab, Standard Chemotherapy, Gen1055
Malignant Solid Tumor
Phase I/II
Active Not Recruiting
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Apr 25, 2024
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Genmab A/S (GMAB) have in its pipeline
GMAB is currently developing the following drugs: Rina-S, Ic, Bevacizumab, Bnt327, Bnt314, Soc Chemotherapy Treatment 1, Soc Chemotherapy Treatment 2, Pembrolizumab, Acasunlimab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.